Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.

Wentink MQ, Broxterman HJ, Lam SW, Boven E, Walraven M, Griffioen AW, Pili R, van der Vliet HJ, de Gruijl TD, Verheul HM.

Br J Cancer. 2016 Oct 11;115(8):940-948. doi: 10.1038/bjc.2016.275.

PMID:
27575850
2.

The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance.

Alidzanovic L, Starlinger P, Schauer D, Maier T, Feldman A, Buchberger E, Stift J, Koeck U, Pop L, Gruenberger B, Gruenberger T, Brostjan C.

Oncotarget. 2016 Aug 30;7(35):57197-57212. doi: 10.18632/oncotarget.11084.

3.

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F.

Oncotarget. 2016 Feb 23;7(8):9309-21. doi: 10.18632/oncotarget.7008.

4.

Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice.

Jo DH, Park SW, Cho CS, Powner MB, Kim JH, Fruttiger M, Kim JH.

PLoS One. 2015 Jul 30;10(7):e0134308. doi: 10.1371/journal.pone.0134308.

5.

Molecular mechanism matters: Benefits of mechanistic computational models for drug development.

Clegg LE, Mac Gabhann F.

Pharmacol Res. 2015 Sep;99:149-54. doi: 10.1016/j.phrs.2015.06.002. Review.

6.

A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.

Shen Y, Zeng L, Novosyadlyy R, Forest A, Zhu A, Korytko A, Zhang H, Eastman SW, Topper M, Hindi S, Covino N, Persaud K, Kang Y, Burtrum D, Surguladze D, Prewett M, Chintharlapalli S, Wroblewski VJ, Shen J, Balderes P, Zhu Z, Snavely M, Ludwig DL.

MAbs. 2015;7(5):931-45. doi: 10.1080/19420862.2015.1055442.

7.

Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.

Tsai HL, Lin CH, Huang CW, Yang IP, Yeh YS, Hsu WH, Wu JY, Kuo CH, Tseng FY, Wang JY.

Int J Clin Exp Pathol. 2015 Feb 1;8(2):1900-10.

8.

Systems biology of the microvasculature.

Clegg LE, Mac Gabhann F.

Integr Biol (Camb). 2015 May;7(5):498-512. doi: 10.1039/c4ib00296b. Review.

9.

Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.

Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguin V, Rivière S, Corre R, Bailly S, Paintaud G.

MAbs. 2015;7(3):630-7. doi: 10.1080/19420862.2015.1022693.

10.

Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.

Sharan S, Woo S.

Front Pharmacol. 2015 Feb 20;6:33. doi: 10.3389/fphar.2015.00033.

11.

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients.

Panoilia E, Schindler E, Samantas E, Aravantinos G, Kalofonos HP, Christodoulou C, Patrinos GP, Friberg LE, Sivolapenko G.

Cancer Chemother Pharmacol. 2015 Apr;75(4):791-803. doi: 10.1007/s00280-015-2701-3.

12.

Multiphasic changes in systemic VEGF following intravitreal injections of ranibizumab in a child.

Shao EH, Sivagnanavel V, Dabbagh A, Dave R, Tempest-Roe S, Tam FW, Taylor SR.

Eye (Lond). 2015 Apr;29(4):569-73. doi: 10.1038/eye.2014.343.

13.

Divide and conquer, faster: speeding up molecular simulations.

Mac Gabhann F.

Biophys J. 2015 Feb 3;108(3):455-6. doi: 10.1016/j.bpj.2014.12.026. No abstract available.

14.
15.

Computational systems biology approaches to anti-angiogenic cancer therapeutics.

Finley SD, Chu LH, Popel AS.

Drug Discov Today. 2015 Feb;20(2):187-97. doi: 10.1016/j.drudis.2014.09.026. Review.

16.

Quantitative characterization of cellular membrane-receptor heterogeneity through statistical and computational modeling.

Weddell JC, Imoukhuede PI.

PLoS One. 2014 May 14;9(5):e97271. doi: 10.1371/journal.pone.0097271. Erratum in: PLoS One. 2014;9(8):e107095.

17.
18.

Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Vempati P, Popel AS, Mac Gabhann F.

Cytokine Growth Factor Rev. 2014 Feb;25(1):1-19. doi: 10.1016/j.cytogfr.2013.11.002. Review.

19.

A systems biology view of blood vessel growth and remodelling.

Logsdon EA, Finley SD, Popel AS, Mac Gabhann F.

J Cell Mol Med. 2014 Aug;18(8):1491-508. doi: 10.1111/jcmm.12164. Review.

20.

Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions.

Finley SD, Popel AS.

J Natl Cancer Inst. 2013 Jun 5;105(11):802-11. doi: 10.1093/jnci/djt093.

Items per page

Supplemental Content

Support Center